[心力衰竭中左捆分支区域节奏和重同步]
1Centre hospitalier Aix en Provence Avenue des Tamaris 13100 Aix en Provence, France.
概括
左捆分支阻断节奏 (LBBAP) 为生理心室激活提供了一种可靠的方法,比传统疗法更有前途. 目前正在进行的研究和新设备支持LBBAP作为潜在的第一线治疗心律障碍.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 医疗器械 医疗器械
背景情况:
- 左捆分支阻断节奏 (LBBAP) 是一种新兴的技术,用于实现生理心室激活.
- 它提供了一种更可靠的替代Hisian节奏,并可以解决近距离左捆分支块.
- 来自注册和早期试验的越来越多的证据表明LBBAP的有效性.
研究的目的:
- 与传统的心脏再同步治疗相比,评估LBBAP的好处.
- 评估LBBAP的技术可靠性和临床结果.
- 为开发专门的LBBAP设备提供信息.
主要方法:
- 来自众多注册表和初始小规模随机研究的数据分析.
- 与传统重同步治疗对比LBBAP结果的比较.
- 制造商正在开发并将LBBAP整合到除中.
主要成果:
- 在初步研究中,令人鼓舞的结果有利于LBBAP而不是传统的重同步疗法.
- LBBAP证明了技术可靠性和纠正传导异常的潜力.
- 共识文件承认LBBAP是可行的一线选择,并建议在传统治疗失败后使用LBBAP.
结论:
- 左捆分支阻断节奏是生理心室激活的一个有前途的策略.
- 在早期评估中,LBBAP显示出与传统疗法的优越性或同等性.
- 进一步强大的随机研究正在进行中,以巩固LBBAP在心律管理中的作用.
相关概念视频
Heart Failure Drugs: β-Blockers
771
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
771
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure II: Pathophysiology
730
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
730
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Dysrhythmias IV: Characteristics of Bradyarrhythmias
499
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
499


